Biocon Biologics interchangeable insulin Semglee gets US FDA approval

Biocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in the United States to treat diabetic patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news